Main Menu
Menu

Council for Innovation Promotion

Publish Date
BlogFact Checks
Fact Check: The Data Doesn’t Support the Existence of So-Called Patent “Thickets”

Several academic authors recently published an article in Health Affairs Forefront advising policymakers in Congress and at the USPTO on the best...

Resources
Infographics & Fact Sheets
PREVAIL in Comparison to the Current and Previous Administration’s Procedures for PTAB
News
Fake gifts flooding online marketplaces this holiday season. Here’s how to avoid getting scammed.
KTNV-TV
Blog
‘Tis the Season — of Counterfeits?

Counterfeiting is a multi-billion-dollar enterprise that puts consumers at serious risk. Poorly-made laptop batteries can overheat. Knock-off cosmetics may contain toxic chemicals....

News
The Patent Eligibility Restoration Act (PERA) Could Provide A Much Needed Boost To Key Technology Sectors Of The U.S. Economy
Mondaq
Press Releases
Council for Innovation Promotion Statement on RALIA and the BIA

WASHINGTON (November 10, 2025) — Recently, Representatives Thomas Massie (R-KY), Marcy Kaptur (D-OH), Michael Cloud (R-TX), Warren Davidson (R-OH), Paul Gosar (R-AZ),...

Blog
This Month in IP: October 2025

Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From firefighting...

Blog
C4IP Coalition Updates: October 2025

October Highlights: C4IP Advocates for the Patent Eligibility Restoration Act On October 8, the Senate Judiciary Subcommittee on Intellectual Property held a...

News
C4IP Urges USTR to Use USMCA Joint Review to Address Shortcomings on IP Protections
IPWatchdog
Resources
Public Comments
C4IP Comments RE: India’s Invitation to Comment on Its Drug Approval Regime
Resources
Public Comments
C4IP Comments RE: Operation of the Agreement between the United States of America, the United Mexican States, and Canada (USTR-2025-0004)
Blog
Why Continued Innovation Matters: Keytruda and the “Product Hopping” Myth

The FDA recently approved a new version of Keytruda, a cancer immunotherapy medicine that is one of the world’s most successful drugs....

Resources:

Resources:

C4IP Response to CMS Solicitation of Comments Concerning Initial Guidance on the Inflation Reduction Act’s (IRA) Medicare Drug Negotiation Program,

04/14/2023
Op-Eds:

Op-Eds:

America can defeat China and win the future if we do this one thing,

04/14/2023
News:

News:

Vidal Tells IP Press USPTO Has Been Listening and Learning in Year One—But Now It’s Time for Action,

04/13/2023
Blog:

Blog:

Inventor Spotlight: Ronald J. Harp,

04/13/2023
News:

News:

WHO pushes for more access to COVID-19 drugs,

04/11/2023
Blog:

Blog:

Inventor Spotlight: Chester Greenwood,

04/10/2023
Op-Eds:

Op-Eds:

A Look Into the Growing Reluctance to Fund Startups,

04/06/2023
Op-Eds:

Op-Eds:

Big Tech Has Eviscerated America’s Patent System,

04/05/2023
Blog:

Blog:

Biden’s Cancer Moonshot Won’t Get off the Ground Without Strong IP Protections,

04/05/2023
News:

News:

A US Judge Is Enabling Tech’s Campaign To Crush Startup Competitors,

03/31/2023
Resources:

Resources:

C4IP Post-Hearing Brief RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities,

03/29/2023
Resources:

Resources:

C4IP Post-Hearing Brief RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities,

03/29/2023
Scroll to Top